GlassScriptPhysician profile
David R Rosencrantz
NPI 1750393534
$837.24
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $128 · 2021: $65.36 · 2022: $87.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $214.15 | 2019 | |
| Ferring Pharmaceuticals INC. | $186.33 | 2019-2020 | |
| Olympus America INC. | $170.73 | 2019-2022 | |
| Pfizer INC. | $65.55 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $51.08 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $48.90 | 2020-2021 | |
| Antares Pharma, INC. | $41.29 | 2020 | |
| Amgen INC. | $15.64 | 2021 | |
| Coloplast Corp | $15.00 | 2020 | |
| Abbvie INC. | $12.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 | |
| Travere Therapeutics, INC. | $8.00 | 2019-2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rosencrantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.